London
· Delayed Price · Currency is GBP · Price in GBXGenflow Biosciences Statistics
Total Valuation
Genflow Biosciences has a market cap or net worth of GBP 6.12 million. The enterprise value is 4.98 million.
| Market Cap | 6.12M |
| Enterprise Value | 4.98M |
Important Dates
The next estimated earnings date is Friday, December 27, 2024.
| Earnings Date | Dec 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genflow Biosciences has 349.71 million shares outstanding. The number of shares has increased by 3.90% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 349.71M |
| Shares Change (YoY) | +3.90% |
| Shares Change (QoQ) | +8.74% |
| Owned by Insiders (%) | 51.04% |
| Owned by Institutions (%) | 22.03% |
| Float | 164.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.94 |
| PB Ratio | 7.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.25 |
| EV / Sales | 8.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.94 |
Financial Position
The company has a current ratio of 2.73
| Current Ratio | 2.73 |
| Quick Ratio | 2.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -118.87% and return on invested capital (ROIC) is -74.30%.
| Return on Equity (ROE) | -118.87% |
| Return on Assets (ROA) | -58.66% |
| Return on Capital (ROIC) | -74.30% |
| Revenue Per Employee | 119,608 |
| Profits Per Employee | -306,285 |
| Employee Count | 5 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.91% in the last 52 weeks. The beta is 2.37, so Genflow Biosciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.37 |
| 52-Week Price Change | -6.91% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 2.03 |
| Relative Strength Index (RSI) | 37.71 |
| Average Volume (20 Days) | 336,633 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genflow Biosciences had revenue of GBP 598,041 and -1.53 million in losses. Loss per share was -0.01.
| Revenue | 598,041 |
| Gross Profit | 598,041 |
| Operating Income | -1.53M |
| Pretax Income | -1.53M |
| Net Income | -1.53M |
| EBITDA | -1.53M |
| EBIT | -1.53M |
| Loss Per Share | -0.01 |
Balance Sheet
| Cash & Cash Equivalents | 1.14M |
| Total Debt | n/a |
| Net Cash | 1.14M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 858,345 |
| Book Value Per Share | 0.00 |
| Working Capital | 854,889 |
Cash Flow
In the last 12 months, operating cash flow was -1.01 million and capital expenditures 1,346, giving a free cash flow of -1.01 million.
| Operating Cash Flow | -1.01M |
| Capital Expenditures | 1,346 |
| Free Cash Flow | -1.01M |
| FCF Per Share | -0.00 |
Margins
Gross margin is 100.00%, with operating and profit margins of -256.10% and -256.07%.
| Gross Margin | 100.00% |
| Operating Margin | -256.10% |
| Pretax Margin | -256.07% |
| Profit Margin | -256.07% |
| EBITDA Margin | -255.89% |
| EBIT Margin | -256.10% |
| FCF Margin | -168.66% |
Dividends & Yields
Genflow Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.90% |
| Shareholder Yield | -3.90% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genflow Biosciences has an Altman Z-Score of 0.21. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.21 |
| Piotroski F-Score | n/a |